Clear data supporting very high immune escape potential of Omicron: INSACOG

The genomic consortium, citing global data, said there is now clear experimental and clinical data supporting very high immune escape potential of Omicron, which appears to be the major component of its growth advantage over Delta

There is now clear experimental and clinical data supporting very high immune escape potential of Omicron, but initial estimates show the severity of illness being lower than what was seen in previous outbreaks, the Indian SARS-COV-2 Genomics Consortia INSACOG said in its latest bulletin citing global data.

In India, appropriate public health measures and investigations are being conducted for surveillance of Omicron, INSACOG said while noting that globally there appears to be significantly reduced ability of vaccines or prior infection to protect against symptomatic infection by the Omicron variant.

“While Delta continues to be the most prevalent VOC globally, the Omicron variant has completely displaced it in southern Africa and is on track to become the dominant variant in U.K. and elsewhere,” INSACOG said in its bulletin released on December 29.